Saturday, November 28, 2020 10:18:17 AM
FDA Device Database
as a result of this Clinical Trial:
Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children
Trial started January 2015 and currently listed as "Active, not recruiting". There is an article listed near the bottom of that link. If you click on that article, then in it click on Similar Articles and Cited By, you will find a lot of information related to this type of treatment.
I just took a quick look at some of the information in those links; you will find a lot of very good information. One that I liked a lot is here:
Magnetic Resonance Imaging-guided High-intensity Focused Ultrasound Applications in Pediatrics: Early Experience at Children's National Medical Center
Although clinical experience in pediatrics is relatively small, the advantages of a completely noninvasive and radiation-free therapy are especially attractive to growing children. Unlike elderly patients, young children must deal with an entire lifetime of negative effects related to collateral tissue damage associated with invasive surgery, side effects of chemotherapy, and risk of secondary malignancy due to radiation exposure. These reasons provide a clear rationale and strong motivation to further advance clinical utility of MR-HIFU in pediatrics.
Nice information. Will love to see what the company says about all of this. It may force me to change my current thinking on this company. Currently I'm using a 2/3rd Core, 1/3 Trading position. Might have to stop trading for a while.
Shout-out to hayfarmer for the tip on this company. Been trading it for a while and have done well. But this is looking even better now.
Recent PROF News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/17/2024 08:45:04 PM
- Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow • GlobeNewswire Inc. • 10/17/2024 08:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/16/2024 08:30:04 PM
- Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer • GlobeNewswire Inc. • 10/16/2024 08:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/23/2024 08:42:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/16/2024 12:15:04 PM
- Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA • GlobeNewswire Inc. • 09/16/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/12/2024 10:02:56 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 09/04/2024 09:02:36 PM
- Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference • GlobeNewswire Inc. • 09/04/2024 08:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 04:15:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/27/2024 05:31:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/08/2024 08:50:57 PM
- Profound Medical Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 08:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/18/2024 08:45:04 PM
- Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow • GlobeNewswire Inc. • 07/18/2024 08:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/16/2024 04:15:13 AM
- Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases • GlobeNewswire Inc. • 07/11/2024 11:00:00 AM
- Form F-X - Appointment of Agent for Service of Process and Undertaking • Edgar (US Regulatory) • 06/14/2024 09:23:52 PM
- Form F-10 - Registration Statement for Securities of certain Canadian Issuers. • Edgar (US Regulatory) • 06/14/2024 09:01:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/14/2024 08:05:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 08:30:07 PM
- Profound Medical Annual General Meeting of Shareholders Voting Results • GlobeNewswire Inc. • 05/15/2024 09:00:00 PM
- PROFOUND MEDICAL ANNUAL GENERAL MEETING OF SHAREHOLDERS VOTING RESULTS • PR Newswire (Canada) • 05/15/2024 08:12:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM